Published in FASEB J on October 25, 2006
Malaria impairs resistance to Salmonella through heme- and heme oxygenase-dependent dysfunctional granulocyte mobilization. Nat Med (2011) 2.04
Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology (2007) 1.59
Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE/ARE sequence motif at position -7007 of the FPN1 promoter. Haematologica (2010) 1.47
MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology (2010) 1.38
Induction of heme oxygenase 1 attenuates placental ischemia-induced hypertension. Hypertension (2011) 1.14
Oxidative stress fuels Trypanosoma cruzi infection in mice. J Clin Invest (2012) 1.08
The let-7 microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates oxidant injury in human hepatocytes. Biochim Biophys Acta (2012) 1.08
Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. Liver Int (2008) 1.05
Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells. World J Gastroenterol (2009) 1.02
Oxidative stress response and Nrf2 signaling in aging. Free Radic Biol Med (2015) 0.99
Are reactive oxygen species always detrimental to pathogens? Antioxid Redox Signal (2013) 0.95
Cobalt protoporphyrin accelerates TFEB activation and lysosome reformation during LPS-induced septic insults in the rat heart. PLoS One (2013) 0.94
Zinc mesoporphyrin induces rapid and marked degradation of the transcription factor Bach1 and up-regulates HO-1. Biochim Biophys Acta (2008) 0.93
Boolean modeling and fault diagnosis in oxidative stress response. BMC Genomics (2012) 0.90
Hepcidin suppression and defective iron recycling account for dysregulation of iron homeostasis in heme oxygenase-1 deficiency. J Cell Mol Med (2009) 0.90
The role of Bach1 in the induction of heme oxygenase by tin mesoporphyrin. Biochem Biophys Res Commun (2007) 0.89
Heme oxygenase-1 induction enhances cell survival and restores contractility to unvascularized three-dimensional adult cardiomyocyte grafts implanted in vivo. Tissue Eng Part A (2011) 0.89
The role of nrf2 and cytoprotection in regulating chemotherapy resistance of human leukemia cells. Cancers (Basel) (2011) 0.88
Cobalt protoporphyrin as a potential therapeutic agent? FASEB J (2007) 0.88
Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells. Br J Pharmacol (2014) 0.87
Heme oxygenase-1 induction does not improve vascular relaxation in angiotensin II hypertensive mice. Am J Hypertens (2008) 0.86
Iron-based redox switches in biology. Antioxid Redox Signal (2009) 0.85
Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV. World J Gastroenterol (2011) 0.83
Metalloporphyrins - an update. Front Pharmacol (2012) 0.83
Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis. Adv Pharmacol Sci (2010) 0.82
Kaposi Sarcoma Herpesvirus Induces HO-1 during De Novo Infection of Endothelial Cells via Viral miRNA-Dependent and -Independent Mechanisms. MBio (2015) 0.81
Mitochondrial function provides instructive signals for activation-induced B-cell fates. Nat Commun (2015) 0.81
Nuclear factor erythroid 2-related factor 2 regulates toll-like receptor 4 innate responses in mouse liver ischemia-reperfusion injury through Akt-forkhead box protein O1 signaling network. Transplantation (2014) 0.81
Crocin suppresses LPS-stimulated expression of inducible nitric oxide synthase by upregulation of heme oxygenase-1 via calcium/calmodulin-dependent protein kinase 4. Mediators Inflamm (2014) 0.81
Distribution and localization of fibroblast growth factor-8 in rat brain and nerve cells during neural stem/progenitor cell differentiation. Neural Regen Res (2012) 0.79
Cobalt protoporphyrin induces HO-1 expression mediated partially by FOXO1 and reduces mitochondria-derived reactive oxygen species production. PLoS One (2013) 0.78
Homocysteine downregulates gene expression of heme oxygenase-1 in hepatocytes. Nutr Metab (Lond) (2014) 0.78
Gold nanoparticles induce heme oxygenase-1 expression through Nrf2 activation and Bach1 export in human vascular endothelial cells. Int J Nanomedicine (2015) 0.77
Changes in expression and secretion patterns of fibroblast growth factor 8 and Sonic Hedgehog signaling pathway molecules during murine neural stem/progenitor cell differentiation in vitro. Neural Regen Res (2012) 0.77
Effects of zinc deuteroporphyrin bis glycol on newborn mice after heme loading. Pediatr Res (2011) 0.76
Characterization of docosahexaenoic acid (DHA)-induced heme oxygenase-1 (HO-1) expression in human cancer cells: the importance of enhanced BTB and CNC homology 1 (Bach1) degradation. J Nutr Biochem (2014) 0.76
Drug Transporter Expression and Activity in Human Hepatoma HuH-7 Cells. Pharmaceutics (2016) 0.75
Cobalt(III) Protoporphyrin Activates the DGCR8 Protein and Can Compensate microRNA Processing Deficiency. Chem Biol (2015) 0.75
A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells. Oncotarget (2016) 0.75
Can Cytoprotective Cobalt Protoporphyrin Protect Skeletal Muscle and Muscle-derived Stem Cells From Ischemic Injury? Clin Orthop Relat Res (2015) 0.75
Modulation of antigen processing by haem-oxygenase 1. Implications on inflammation and tolerance. Immunology (2016) 0.75
The Cytoprotective Effects of E-α-(4-Methoxyphenyl)-2',3,4,4'-Tetramethoxychalcone (E-α-p-OMe-C6H4-TMC)-A Novel and Non-Cytotoxic HO-1 Inducer. PLoS One (2015) 0.75
Heme oxygenase and carbon monoxide protect from muscle dystrophy. Skelet Muscle (2016) 0.75
Heme status affects human hepatic messenger RNA and microRNA expression. World J Gastroenterol (2013) 0.75
Aging-related decline in the induction of Nrf2-regulated antioxidant genes in human bronchial epithelial cells. Redox Biol (2017) 0.75
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med (2005) 2.95
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology (2012) 2.61
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int (2012) 2.10
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med (2006) 1.95
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl (2005) 1.76
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology (2010) 1.71
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Hereditary hemochromatosis: time for targeted screening. Ann Intern Med (2008) 1.60
Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology (2007) 1.59
Effect of hepatic artery flow on bile secretory function after cold ischemia. Am J Transplant (2003) 1.40
MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology (2010) 1.38
Drug-induced liver injury associated with statins. Semin Liver Dis (2009) 1.36
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci (2013) 1.31
Iron in nonhemochromatotic liver disorders. Semin Liver Dis (2005) 1.25
Role of Bach-1 in regulation of heme oxygenase-1 in human liver cells: insights from studies with small interfering RNAS. J Biol Chem (2004) 1.22
Serum measures of iron status and HFE gene mutations in patients with hepatitis B virus infection. Hepatol Res (2007) 1.20
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis (2006) 1.19
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology (2009) 1.18
microRNAs: fad or future of liver disease. World J Gastroenterol (2011) 1.15
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology (2006) 1.13
Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (2010) 1.12
Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol (2003) 1.12
Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol (2013) 1.10
HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells. J Hepatol (2006) 1.10
The let-7 microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates oxidant injury in human hepatocytes. Biochim Biophys Acta (2012) 1.08
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology (2009) 1.08
Autoimmune hepatitis triggered by statins. J Clin Gastroenterol (2006) 1.06
Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. Liver Int (2008) 1.05
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology (2005) 1.05
The diagnosis and management of erythropoietic protoporphyria. Gastroenterol Hepatol (N Y) (2008) 1.04
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One (2011) 1.04
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology (2009) 1.03
Novel role of nuclear receptor Rev-erbα in hepatic stellate cell activation: potential therapeutic target for liver injury. Hepatology (2014) 1.02
Hepatic porphyrias: diagnosis and management. Clin Liver Dis (2004) 1.00
Fatal air and bile embolism after percutaneous liver biopsy and ERCP. Gastrointest Endosc (2005) 1.00
Lon peptidase 1 (LONP1)-dependent breakdown of mitochondrial 5-aminolevulinic acid synthase protein by heme in human liver cells. J Biol Chem (2011) 0.99
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 0.98
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology (2011) 0.98
Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern. J Hepatol (2006) 0.97
CTL escape mutations of core protein are more frequent in strains of HBeAg negative patients with low levels of HBV DNA. J Clin Virol (2009) 0.97
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol (2008) 0.96
Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology (2011) 0.95
Structural analysis of heme proteins: implications for design and prediction. BMC Struct Biol (2011) 0.95
Hemochromatosis mutations in Iranians with hepatitis B virus infection. Clin Infect Dis (2004) 0.95
The neuromediator glutamate, through specific substrate interactions, enhances mitochondrial ATP production and reactive oxygen species generation in nonsynaptic brain mitochondria. J Biol Chem (2009) 0.95
Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy. World J Gastroenterol (2013) 0.95
Intestinal expression of genes involved in iron absorption in humans. Am J Physiol Gastrointest Liver Physiol (2002) 0.93
Zinc mesoporphyrin induces rapid and marked degradation of the transcription factor Bach1 and up-regulates HO-1. Biochim Biophys Acta (2008) 0.93
Genetic aspects of porphyria cutanea tarda. Semin Liver Dis (2007) 0.93
Parallel microRNA and mRNA expression profiling of (genotype 1b) human hepatoma cells expressing hepatitis C virus. Liver Int (2010) 0.91
Differential regulation of human ALAS1 mRNA and protein levels by heme and cobalt protoporphyrin. Mol Cell Biochem (2008) 0.91
Iron as a comorbid factor in chronic viral hepatitis. Am J Gastroenterol (2002) 0.90
Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells. Gastroenterology (2009) 0.90
Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2011) 0.90
Vascular endothelial growth factor increases heme oxygenase-1 protein expression in the chick embryo chorioallantoic membrane. Br J Pharmacol (2003) 0.88
Mapping of the chick heme oxygenase-1 proximal promoter for responsiveness to metalloporphyrins. Arch Biochem Biophys (2002) 0.88